Inside Story Behind Glybera's Development and Approval
Late last year the European Medicines Agency granted marketing approval for the Western world's first gene therapy product, Glybera. During this SKYPE interview, James M. Wilson, M.D., Ph.D., one of the researchers who led the Glybera team, discusses the ups and downs and ins and outs of not only developing the new therapeutic but also gaining regulatory approval for the novel product. JMW is an inventor on the AAV1 patent and will receive royalties from the sales of Glybera.
GEN videos are informative, entertaining, and encompass all aspects of biotechnology. To get details on how to submit your own, click here.
-
Inside Story Behind Glybera's Development and Approval
-
Late last year the European Medicines Agency granted marketing approval for the Western world's first gene therapy product, Glybera. During this SKYPE interview, James M. Wilson, M.D., Ph.D., one of the researchers who led the Glybera team, discusses the ups and downs and ins and outs of not only developing the new therapeutic but also gaining regulatory approval for the novel product. JMW is an inventor on the AAV1 patent and will receive royalties from the sales of Glybera.
-
FlexMoSys™ flexible, modular and fully integrated solutions
-
The Combination of Complementary Expertise for the Next Generation of Flexible, Single-Use Manufacturing Concepts.
Sartorius Stedim Biotech’s well-established, single-use and reusable product portfolio and G-Con Manufacturing’s novel, modular, mobile cleanroom “pods” provide an unparalleled set of cost-effective, “plug and play” tools for next-generation biomanufacturing.
-
2012 BIO International Convention
-
This month, the 2012 BIO International Convention will bring together a vastly transformed global industry poised to address the monumental public health challenges facing our world today. Since our event is taking place during a time of great change for our industry, I believe this is truly a can’t-miss opportunity to connect with industry leaders to accelerate your next breakthrough. To read more from Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), click here.
-
James Wilson, M.D., Ph.D., on gene therapy as a disruptive technology
-
Dr. James Wilson is a professor in the department of pathology and laboratory medicine, and the director of the gene therapy program, at the University of Pennsylvania. He is also the editor of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. During this interview with GEN, Dr. Wilson discusses his concept of a disruptive technology and explains why he believes gene therapy falls into this category.
In addition to this SKYPE interview, Dr. Wilson further elaborated on his view of gene therapy as a disruptive technology in a column in the January 2012 issue of Human Gene Therapy which you can access by clicking here.
-
Mark Heesen on Funding Challenges
-
GEN interviews Mark Heesen, president of the National Venture Capital Association, about funding challenges for the biotechnology sector. For more creative financing tips, click here.
-
Ji-Joon Song, Ph.D., on ChemiDoc MP
-
Find out why Ji-Joon Song, Ph.D., assistant professor in the department of biological sciences at the Korean Advanced Institute of Science and Technology, prefers the ChemiDoc MP. Additional details on the ChemiDoc MP can be found here.
-
Dana Carroll, Ph.D., on ZFN Technology
-
Dr. Carroll, professor at the University of Utah and one of the originators of zinc finger nuclease (ZFN) technology, reflects on the platform’s potential for genetics. To learn more about Sigma Aldrich’s ZFN technology, click here.
-
George Church, Ph.D., on Cloning a Neanderthal
-
Dr. Church, professor of genetics at Harvard Medical School and director of the Center for Computational Genetics, skypes with GEN and discusses why he thinks it is a good idea to clone a Neanderthal.
-
Hollow Fiber Modified Polyethersulfone Filters
-
Modified Polyethersulfone (mPES) is an advanced hydrophilic membrane filtration chemistry that provides higher flux rates for faster processing times, excellent selectivity for separation applications, and low protein binding for higher product yields than other membranes.